What is trending? - Peptides in Vaccine Development

Originally vaccines provided immunity against infectious diseases but their broad success has also led to advancements in their specified application towards cancer and other malignant diseases. Moreover, recent advancements in mRNA vaccine technology have paved the way more targeted, effective and rapid vaccine developments. 

From cancer to autoimmune disorders and infectious diseases, our peptides are paving the way for more targeted, effective vaccines! 

Our peptides provide a suitable approach to study the efficacy of vaccines by testing for humoral and cellular immune responses, for target discovery or making use of peptides as vaccine agents. 

• Cellular and Humoral Immune Monitoring : Our peptide formats allow efficient profiling of antigen-specific cellular immune responses by cellular assays such as ELISPOT and Flow Cytometry. 
• T Cell and B Cell Target & Epitope Discovery : deep discovery, confirmation, and qualification of T-cell antigen targets, immune dominant epitopes and neo-epitopes, thus enabling detection of vaccine targets from a variety of antigens or even pathogenic proteomes in infectious diseases and cancer. Moreover, JPT offers a large variety of platforms for B-cell epitope discovery, antibody epitope mapping, humoral immune response profiling, elucidation of antibody binding pattern, and validation of protein interactions. 
• Tumor Antigen Vaccines : Somatic mutations within tumor cells give rise to tumor-specific MHC I restricted epitopes that can be recognized by the immune system to differentiate cancer from normal cells. Thus, generally occurring shared tumor antigens (e.g. KRAS) are candidates for cancer vaccines. A tumor antigen vaccine made of tumor antigens (peptides) stimulates the host's immune system to neutralize cancer cells. Our Clinical Peptides and Pools meet the need for high quality yet fast and affordable peptides for development of vaccines such as melanoma, breast, and prostate cancer. 

Applications of Our Peptide Technologies 

ake advantage of our custom or ready-to-use peptides. We offer single antigen peptides, peptide pools and libraries, peptide microarrays, and stable isotope labeled (heavy) peptides covering the following: 

• Human tumor-associated antigens: Melanoma, prostate cancer, breast cancer, colon cancer, lymphoma and more
• Infectious Disease antigens: Coronaviruses, SARS-CoV-2, several tropical disease viruses, hAdV, AAV5, HIV, EBV, HCMV, HPV, Influenza, RSV, Monkeypox and many more 

Selected Papers: 

Many strides have been made towards fine-tuning and optimizing the mRNA method, and in developing vaccines against cancers and infectious diseases. Check out the following selection of this years’ publications covering said topics! For a broader selection, take a look at our references and application notes.

1. Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5
   Gan et al., Journal of Translational Medicine (2025)
   Products used: PepMix™ Human (FJX1), PepMix™ Human (MAGED4) 
2. A vaccine targeting lung resident-memory CD4+ T cell phenotype protects against Mycobacterium tuberculosis in mice
   Ko et al., NPJ Vaccines (2025) – PMID: 40695843
   Products used: PepMix™ M. tuberculosis (CFP-10), PepMix™ M. tuberculosis (ESAT-6)
3. Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses
   Meyer et al., Nature Communications (2025) – PMID: 40595473
   Products used: Custom PepStar of MARV variant Angola (UniProtKB/Swiss-Prot: Q1PD50.1) and RAVV (NCBI Reference sequence: YP_009055225.1) 
4. Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals
   Sánchez-Simarro et al., Journal of Medical Virology (2025) – PMID: 40545672
   Products used: PepMix™ SARS-CoV-2 (Spike JN.1), PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
5. Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors
   Sethi et al., NPJ Vaccines (2025)
   Products used: PepMix™ VZV (gE), PepMix™ HPV 18 (L1) or PepMix™ HPV16 (L1) 
6. mRNA-LNP Vaccine Strategies: Effects of Adjuvants on Non-parenchymal Liver Cells and Tolerance
   Svensson et al., Methods & Clinical Development (2025)
   Product used: OVA (257-264) Chicken Ovalbumin Peptide - SIINFEKL 
7. Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection
   Wørzner et al., eBiomedicine (2025) – PMID: 39983329
   Product used: Custom Antigen Peptide VTWFHAIHVSGTNGT 
8. Immunogenicity of RSV Fusion Protein Adsorbed to Non-Pathogenic Bacillus subtilis Spores: Implications for Mucosal Vaccine Delivery in Nonclinical Animal Models
   Xiao et al., Biomedicines (2025)
   Products used: Custom PepMix, RSV F protein 
9. Pregnancy and lactation induce distinct immune responses to COVID-19 booster vaccination and SARS-CoV-2 breakthrough infection
   Yin et al., JCI Insight (2025) – PMID: 40693463
   Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 

Do you have any more questions? 

Besides peptide-based vaccination, we also offer peptides to develop cell- and immunotherapies or gene therapy. Reach out! Our team of experts is always here to support your research needs. Contact us today to inquire about our peptide tools or send us a quote request for custom options!